EGFR and non-small cell lung carcinoma: Within the realm of EGFR-TKIs, the third-generation variant, osimertinib, exhibited substantially higher rates of QT interval prolongation compared to other EGFR-TKIs (ROR = 49.19, 99% CI: 25.88–93.47), other targeted NSCLC therapies (ROR = 6.13, 99% CI: 4.43–8.48), and the overall VigiBase database (ROR = 14.34, 99% CI: 10.79–19.04, IC025 = 3.38).